Table 3. Two-year clinical outcomes according to type of drug-eluting stent.
| Outcomes | BES (n=472) | ZES (n=464) | Absolute difference (90% CI) | Hazard ratio (90% CI) | p value | ||
|---|---|---|---|---|---|---|---|
| Primary outcome | |||||||
| MACE | 52 (11.2) | 50 (10.9) | 0.33 (−3.12, 3.77) | 1.00 (0.72, 1.38) | 0.994 | ||
| Secondary outcomes | |||||||
| Death from any cause | 14 (2.8) | 12 (2.7) | 0.11 (−1.67, 1.90) | 1.13 (0.59, 2.16) | 0.758 | ||
| Cardiac | 8 (1.5) | 10 (2.2) | −0.70 (−2.19, 0.79) | 0.77 (0.35, 1.69) | 0.588 | ||
| Non-cardiac | 6 (1.3) | 2 (0.5) | 0.82 (−0.20, 1.84) | 2.91 (0.76, 11.13) | 0.191 | ||
| Myocardial infarction | 10 (2.1) | 13 (2.6) | −0.47 (−2.11, 1.17) | 0.74 (0.37, 1.49) | 0.483 | ||
| Peri-procedure MI | 6 (1.2) | 9 (1.9) | −0.67 (−2.02, 0.68) | 0.65 (0.27, 1.55) | 0.418 | ||
| Spontaneous MI | 4 (0.9) | 4 (0.7) | 0.20 (−0.76, 1.16) | 0.95 (0.30, 3.04) | 0.940 | ||
| Any revascularization | 31 (6.7) | 31 (6.9) | −0.31 (−3.08, 2.47) | 0.96 (0.63, 1.46) | 0.876 | ||
| Target-vessel | 31 (6.7) | 31 (6.9) | −0.31 (−3.08, 2.47) | 0.96 (0.63, 1.46) | 0.876 | ||
| Target-lesion | 19 (4.1) | 21 (4.7) | −0.63 (−2.98, 1.75) | 0.87 (0.52, 1.46) | 0.656 | ||
| Definite stent thrombosis | 1 (0.2) | 0 (0.0) | - | - | 0.301 | ||
| Target-vessel failure | 46 (10.0) | 48 (10.4) | −0.43 (−3.85, 2.88) | 0.92 (0.66, 1.29) | 0.687 | ||
| Target-lesion failure | 35 (7.7) | 38 (8.3) | −0.55 (−3.46, 2.45) | 0.88 (0.60, 1.30) | 0.600 | ||
Values are number of events, percentages (Kaplan–Meier estimates), and hazard ratio (90% CI). Target-vessel failure was defined as a composite of death from cardiac causes, target-vessel MI, or target-vessel revascularization.
BES = biolimus A9-eluting stent; CI = confidence interval; MACE = major adverse cardiovascular events; MI = myocardial infarction; ZES = zotarolimus-eluting stent.